TALK: How to deal with section 3d of the Indian Patent Act: Risks and opportunities
Timo Minssen speaks at "Innovation vs Replication: Can IPR be safeguarded in India?
Abstract
This presentation will discuss the Indian Supreme Court's decision in the Novartis/Gleevec case concerning the Constitutional validity and scope of Sec. 3(d) of the Indian Patents Act. This case has clarified the legislative intent behind various key provisions in the Indian Patents Act. It also raises crucial issues regarding India's compliance with TRIPS and the patentability of formulation inventions. The main objective of this session is to analyze the background and practical impact of this decision in order to identify challenges and opportunities for companies entering the Indian market.
Time: 18 September 2015, 10:20-11:00
Place: Faculty of Law, University of Copenhagen, Studiegaarden, Studiestraede 6, DK-1455 Copenhagen K
Organizer: Innovation Centre Denmark, New Dehli, Bangalore. University of Copenhagen. Bio People.